Diagnostic yield of screening colonoscopy in Hodgkin lymphoma survivors - DICHOS

Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 259 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•HL diagnosis at the age of 16-50 years
•Treatment for HL between 1965 and 2007
•Treatment of primary or recurrent HL consisting of
•o infradiaphragmatic radiotherapy (any field(s)) and chemotherapy (any regimen)
•o infradiaphragmatic radiotherapy consisting of at least para-aortal and iliac fields
•o chemotherapy containing a cumulative procarbazine dose of >=2.8 g/m2
•(e.g. >=2 MOPP, >=4 BEACOPP or >=4 MOPP/ABV courses)
•Survival of at least 8 years after the first treatment that included infradiaphragmatic radiotherapy and chemotherapy or procarbazine-containing chemotherapy
•Age of 25 years or older
•Life expectancy of five years or more

•Proctocolectomy
•Colonoscopy surveillance for other indications (including hereditary CRC syndrome, familial CRC syndrome, inflammatory bowel disease, history of colorectal adenoma or CRC)
•Colonoscopy in the past five years
•On-going cytotoxic treatment or radiotherapy for malignant disease
•Coagulopathy (prothrombin time < 50% of control; partial thromboplastin time > 50 seconds) or anticoagulants (marcoumar, acenocoumarol or new oral anticoagulants) that cannot be stopped
•Comorbidity leading to an impaired physical performance (World health organization (WHO) performance status 3-4) or mental retardation
•No informed consent

发起方

Antoni van Leeuwenhoek Ziekenhuis